Artelo Biosciences: Boral Capital Maintains Buy Rating, PT Raised to $18.

Artelo Biosciences: Boral Capital Maintains Buy Rating, PT Raised to $18.

Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical stage biopharmaceutical company, has received a positive update from Boral Capital. The investment firm has maintained its "buy" rating on Artelo Biosciences, while raising its price target (PT) to $18. This update comes amidst recent positive developments for the company, including a significant increase in stock price and a recent patent allowance.

Artelo Biosciences, which focuses on developing therapeutics that target lipid-signaling pathways, reported a quarterly adjusted loss of $5.61 per share for the quarter ended June 30, 2025. This loss was lower than the same quarter last year, when the company reported EPS of $-4.50. Despite the loss, the company's stock has seen substantial growth, increasing by 52.8% so far this year, following a 26.8% decrease during the quarter.

Boral Capital's decision to raise the price target to $18 reflects a bullish outlook on the company's prospects. The investment firm's analysts have noted the potential of Artelo Biosciences' pipeline, which includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer, and ART12.11, a synthetic cannabidiol cocrystal for various indications.

The company also recently received a Notice of Allowance from the European Patent Office for the patent claims for the intended commercial formulation of ART27.13. This patent allowance is a significant milestone for Artelo Biosciences, as it brings the company closer to commercializing its innovative therapeutic.

Investors should note that Artelo Biosciences' stock has been the subject of limited analyst coverage, with only two research reports in the past 90 days. However, the consensus rating remains strong, with a score of 3.60, indicating a high level of confidence in the company's prospects.

In conclusion, Artelo Biosciences continues to make strides in its clinical development efforts, with recent patent allowance and a positive update from Boral Capital. The company's strong pipeline and growing stock price make it an attractive investment opportunity for those in the biopharmaceutical sector.

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/ARTL/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U50U8:0-artelo-biosciences-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/